A critical overview on ticagrelor in acute coronary syndromes

Simple item page
dc.contributor.authorNavarese, Eliano Pio
dc.contributor.authorBuffon, Antonino
dc.contributor.authorKoziński, Marek
dc.contributor.authorObońska, Karolina
dc.contributor.authorRychter, Marcin
dc.contributor.authorKunadian, Vijay
dc.contributor.authorAustin, David
dc.contributor.authorDe Servi, Stefano
dc.contributor.authorSukiennik, Adam
dc.contributor.authorKubica, Jacek
dc.date.accessioned2013-04-17T12:10:55Z
dc.date.available2013-04-17T12:10:55Z
dc.date.issued2013-04-17
dc.description.abstractUntil a few years ago, the mainstay of anti-platelet therapy in patients with acute coronary syndrome (ACS) was the combination of aspirin and clopidogrel, a P2Y12 receptor inhibitor. However, current clinical practice has now changed with the introduction of ticagrelor, a more potent cardiovascular drug than clopidogrel, without the limitations related to clopidogrel therapy. In this review, we provide a critical overview of ticagrelor in ACS, highlight the results with ticagrelor in several subgroups of patients and discuss the future trials.pl
dc.identifier.citationQJM: An International Journal of Medicine, vol. 106, 2, 2013, pp. 105 -115
dc.identifier.issn1460-2393
dc.identifier.urihttp://repozytorium.umk.pl/handle/item/489
dc.language.isoengpl
dc.rightsinfo:eu-repo/semantics/openAccesspl
dc.subjectacute coronary syndromepl
dc.subjectticagrelorpl
dc.subjectcritical overviewpl
dc.titleA critical overview on ticagrelor in acute coronary syndromespl
dc.typeinfo:eu-repo/semantics/articlepl

Files

Original bundle

Thumbnail Image
Name:
A critical overview on ticagrelor in acute coronary syndromes.pdf
Size:
399.38 KB
Format:
Adobe Portable Document Format
Download

License bundle

Thumbnail Image
Name:
license.txt
Size:
1.34 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Artykuły (WL)